In vitro removal of therapeutic drugs with a novel adsorbent system.
OBJECTIVE
Substances in the middle molecular weight range have been shown to play a significant pathogenetic role in as diverse disorders as end-stage renal disease and multiple organ failure. To overcome the limitations in the amount removed by hemofilters, new sorbents with a high biocompatibility are actively being developed. Furthermore, biocompatible sorbents by their nonspecific adsorptive behavior could have great impact on detoxification treatment in exogenous intoxications. We performed an in vitro evaluation of a newly developed highly biocompatible sorbent cartridge (Betasorb((R))), examining its adsorptive capacity concerning therapeutic drugs.


METHODS
Uremic blood spiked with a range of therapeutic drugs was recirculated for 2 h in an in vitro hemoperfusion circuit containing a Betasorb device for hemoperfusion. The drug concentrations before and after the passage of the cartridge were measured, and the total amount removed was calculated.


RESULTS
The sorbent showed effective removal of glycopeptide antibiotics, digoxin, theophylline, phenobarbital, phenytoin, carbamazepine, and valproic acid. Moderate removal could be demonstrated for tacrolimus and cyclosporine A; aminoglycosides were removed to a small extent only.


CONCLUSIONS
Betasorb hemoperfusion shows a potent adsorptive capacity concerning therapeutic drugs (except aminoglycosides) and could be of major value in the treatment of intoxications. On the other hand, drug monitoring and possible adjustments are necessary during Betasorb hemoperfusion to maintain the therapeutic ranges of the drugs in blood.
Reiter
Karl
K
University Children's Hospital, Kinderklinik und Kinderpoliklinik am Dr. von Haunerschen Kinderspital, Munich, Germany.
Bordoni
Valeria
V
Dall'Olio
Giuliano
G
Ricatti
Maria Grazia
MG
Soli
Maurizio
M
Ruperti
Salvatore
S
Soffiati
Giuliano
G
Galloni
Elisabetta
E
D'Intini
Vincenzo
V
Bellomo
Rinaldo
R
Ronco
Claudio
C
D000327:Adsorption; D000900:Anti-Bacterial Agents / Q000097:blood / Q000493:pharmacokinetics; D001672:Biocompatible Materials; D002220:Carbamazepine / Q000097:blood / Q000493:pharmacokinetics; D004077:Digoxin / Q000493:pharmacokinetics; D006020:Glycopeptides; D006464:Hemoperfusion / Q000295:instrumentation*; D006801:Humans; D008954:Models, Biological; D010634:Phenobarbital / Q000097:blood / Q000493:pharmacokinetics; D010672:Phenytoin / Q000097:blood / Q000493:pharmacokinetics; D016060:Sorption Detoxification / Q000295:instrumentation*; D013806:Theophylline / Q000097:blood / Q000493:pharmacokinetics; D014511:Uremia; D014635:Valproic Acid / Q000097:blood / Q000493:pharmacokinetics
D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D006020:Glycopeptides; D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin; D004077:Digoxin; D013806:Theophylline; D010634:Phenobarbital